Nov 2016

transgene

Joint Bookrunner

€ 46.4 million

Rights Issue

Transgene

Transgene focuses on the development of targeted immunotherapies for the treatment of cancer and infectious diseases

Rights issue amounting to €46.4m.
Proceeds will be used to fund its clinical development plan with the launch of seven clinical trials.
Kempen & Co acted as Joint Bookrunner in the transaction.